As drug delivery vehicles, a HER3 aptamer selected via SELEX for the HER3 extracellular domain (ECD) by Dou et al. [141] was investigated for targeted delivery of doxorubicin (DOX), a broad-spectrum chemotherapeutic, to HER3(+) MCF-7 and BT474 BC cell lines. Here, ERBB3 is linked to breast cancer.